Kisqali, Pluvicto Drive Novartis (NVS ... per the Zacks analyst. Deckers' (DECK) HOKA Brand Likely to Fuel Top Line Per Zacks analyst, HOKA, Deckers' flagship brand, has seen notable growth with ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release conference call and live ...

And let's go through each one of these brands in more detail ... And moving to slide nine, Kisqali continued to cement its leadership in metastatic breast cancer, and launched, importantly ...

We have narrowed our search to three large-cap stocks set to report earnings results tomorrow. These are: NVS, RDDT, CHKP.

indicates strong momentum across all key brands in the upcoming quarters. NVS maintains strong momentum on the back of a strong and diverse portfolio with drugs like Entresto, Kesimpta, Kisqali ...

Data from a clinical trial called NATALEE found that patients with this specific type of breast cancer who received a CDK4/6 inhibitor called Ribociclib (sold under brand names Kisqali and Kryxana), ...

and ribociclib (brand name: Kisqali). In a prior phase 3 trial, studies didn't support that Ibrance (when combined with endocrine therapy) prolonged the amount of time before a recurrence in ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali ...

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting marketing authorization ...